dacomitinib-hydrate

escription: Dacomitinib(aslo known as PF299804, PF299; trade name: Vizimpro) is a novel, potent, orally bioavailable, highly selective, irreversible, secondgeneration pan-ErbB inhibitor, mostly to EGFR with with IC50 of 6 nM, 45.7 nM and 73.7 nM for EGFR, ERBB2, and ERBB4, respectively incell-free assays. It has potential antineoplastic activit and iseffective against NSCLCs with EGFR or ERBB2 mutations (resistant togefitinib) as well as those harboring the EGFR T790M mutation. As of Sep29 2018, Dacomitinib has been approved by FDA as first-line agent forthe treatment of NSCLC.

References: Cancer Res. 2007 Dec 15; 67(24):11924-32; Mol Cancer Ther. 2008 Jul; 7(7):1880-9.

Related CAS: 1042385-75-0 (hydrate, Inquiry); 1262034-38-7 (Dacomitinib metabolite M2, Inquiry); 1110813-31-4 (free)